Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
LegoChem Biosciences
LegoChem Biosciences
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Regulatory
SOTIO expands ADC pipeline with LegoChem agreement
The deal includes LCB’s conjugation technology, ConjuAll, and potent linker-payload platform
Research & Development
LegoChem and Iksuda expand ADC license agreement
In April 2020, Iksuda licensed global development and commercialisation rights for three ADC programmes using LCB's ADC linker/toxin platform
Research & Development
Elsevier welcomes six biotech and pharma start-ups to The Hive
Start-ups working on a range of technologies and discoveries — from AI to immunotherapy — receive complimentary access to Elsevier's information solutions to accelerate innovation
Ingredients
Nordic Nanovector and LegoChem Biosciences collaborate to develop novel antibody-drug conjugates (ADCs) targeting leukaemias
Leukemias are orphan diseases with a significant unmet medical need, representing a growing market estimated to be worth more than $5 billion by 2024
Manufacturing
Lonza signs LightPath discovery agreement with LegoChem
To provide pre-clinical material of novel therapeutic compound
Subscribe now